Tech Company Financing Transactions
ImmuneID Funding Round
On 2/18/2021, ImmuneID received $17 million in funding from Longwood Fund, Arch Venture Partners and In-Q-Tel.
Transaction Overview
Company Name
Announced On
2/18/2021
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company plans to use this funding to develop therapeutic programs in areas including severe allergy, autoimmunity, oncology, and infectious disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
650 East Kendall St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. We are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Christoph Westphal
Chief Executive Officer
David Donabedian
Chief Financial Officer
Jeffrey Capello
President
Annalisa D'Andrea
Browse more venture capital transactions:
Prev: 2/18/2021: Peak AI venture capital transaction
Next: 2/18/2021: unybrands venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs